Compare Revvity Inc (RVTY) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Atlassian Corporation PLC — how do they compare? Revvity Inc trades at $117.6 (market cap $12.91B), while Atlassian Corporation PLC trades at $154.34 (market cap $39.10B). The key difference: Atlassian Corporation PLC is far larger — about 3× Revvity Inc's market cap, and Revvity Inc pays a 0.24% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals.
| RVTY | TEAM | |
|---|---|---|
Market Cap | $12.91B | $39.10B |
Sector | Technology | Technology |
52-Week High | $117.75 | $182.36 |
52-Week Low | $82.26 | $57.15 |
Enterprise Value | $15.23B | $39.09B |
Dividend Yield | 0.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.
The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.
Atlassian (TEAM) trades at $155.15, up 2.16% with strong momentum following a 35% surge post-earnings. The stock shows bullish technical signals with moving averages supporting upward trends, though RSI indicates overbought conditions. Fundamentally, revenue growth remains robust at 28% YoY in Q4 2026, with cloud revenue accelerating to 31% and the company achieving its first full year of GAAP profitability. Analyst sentiment is overwhelmingly positive with 67% buy ratings and a $161.93 consensus target.
Outlook remains favorable with AI platform adoption and enterprise deal expansion driving growth, though valuation metrics appear stretched with EV/EBITDA at 184x. Key risks include competitive pressures in software and execution challenges in maintaining cloud momentum. The stock's proximity to 52-week highs suggests potential for consolidation near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
